LFB USA is a division of a European biopharmaceutical group that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases. With a focus on several major therapeutic fields, including hemostasis, immunology and the intensive care environment, the LFB Group is a leading manufacturer of plasma-derived medicinal products worldwide.

Featured Project

97,000 sq. ft. BioPharmacuetical Manufacturing Facility

In anticipation of FDA approval of their innovative drug to treat preeclampsia, LFB USA asked RP Masiello to lead the design/build project for construction of a new, state-of-the-art, biomanufacturing facility in Marlborough, Massachusetts. The facility will be the company’s primary U.S. center for production of therapeutic enzymes and downstream processing for purification and product capture.

This facility requires a range of robust mechanical systems, heavy process piping, environmental controls, ISO 7- 8 cleanroom and laboratory spaces. Having worked with LFB USA for more than 10 years on several renovations and upgrades to their existing facilities in Framingham and Charlton, company leadership was confident in RP Masiello’s ability to deliver the quality required to meet FDA standards for current Good Manufacturing Practices (cGMP) for biopharmaceuticals.